Prialt

Prialt is a brand name of ziconotide, approved by the FDA in the following formulation(s):

PRIALT (ziconotide acetate - injectable; intrathecal)

• 
  Manufacturer: AZUR PHARMA II
  
  Approval date: December 28, 2004
  
  Strength(s): 100MCG/1ML (100MCG/ML) ^[RLD], 500MCG/20ML (25MCG/ML) ^[RLD], 500MCG/5ML (100MCG/ML) ^[RLD]

Has a generic version of Prialt been approved?

No. There is currently no therapeutically equivalent version of Prialt available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prialt. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method of producing analgesia
  Patent 5,364,842
  Issued: November 15, 1994
  Inventor(s): Justice; Alan & Singh; Tejinder & Gohil; Kishor C. & Valentino; Karen L.
  Assignee(s): Neurex Corporation
  A method of producing analgesia and enhancing opiate analgesia is disclosed. The method includes administering TVIA (SNX-185) or MVIIA (SNX-111) omega-conopeptide, or derivative thereof which is characterized by its ability to (a) inhibit voltage-gated calcium channels selectively in neuronal tissue, as evidenced by the peptide's ability to inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind to omega-conopeptide MVIIA binding sites present in neuronal tissue.
  
  Patent expiration dates:
  
  
  • December 30, 2016
    
    ✓ 
    Patent use: TREATMENT OF PAIN
  
  
  
  • December 30, 2016
    
    ✓ 
    Patent use: ANALGESIA
  
  



• 
  Stable omega conopetide formulations
  Patent 5,795,864
  Issued: August 18, 1998
  Inventor(s): Amstutz; Gary Arthur & Bowersox; Stephen Scott & Gohil; Kishorchandra & Adriaenssens; Peter Isadore & Kristipati; Ramasharma
  Assignee(s): Neurex Corporation
  Disclosed are formulations effective to stabilize omega conotoxin peptide preparations at elevated temperatures. Novel omega conopeptides also form part of the invention.
  
  Patent expiration dates:
  
  
  • June 27, 2015
    
    ✓ 
    Drug product
  
  



• 
  Methods for producing analgesia
  Patent 5,859,186
  Issued: January 12, 1999
  Inventor(s): Justice; Alan & Singh; Tejinder & Gohil; Kishor Chandra & Valentino; Karen L. & Miljanich; George P.
  Assignee(s): Neurex Corporation
  A method of producing analgesia in nociceptive and neuropathic pain is disclosed. The method includes administering to a subject an omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed are novel omega conotoxin peptides effective in producing analgesia.
  
  Patent expiration dates:
  
  
  • December 30, 2011
    
    ✓ 
    Patent use: ANALGESIA
  
  
  
  • December 30, 2011
    
    ✓ 
    Patent use: TREATMENT OF PAIN
  
  

See also...

• Prialt Consumer Information (Drugs.com)
• Prialt Consumer Information (Wolters Kluwer)
• Prialt Consumer Information (Cerner Multum)
• Prialt Advanced Consumer Information (Micromedex)
• Prialt AHFS DI Monographs (ASHP)
• Ziconotide Consumer Information (Drugs.com)
• Ziconotide Consumer Information (Wolters Kluwer)
• Ziconotide Consumer Information (Cerner Multum)
• Ziconotide Intrathecal Advanced Consumer Information (Micromedex)
• Ziconotide AHFS DI Monographs (ASHP)